BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes
When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...
When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...
This is Part 5 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug ...
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech ...
Canary Speech, an AI-enabled voice biomarker technology company, was awarded a patent for the development of its paired neural networks ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.